A Precise Approach to Treating Prostate Cancer: Focal Therapy Program Expands at Mount Sinai
Mount Sinai is expanding its use of an image-guided technology that focuses on removing only cancerous tissue in the prostate, sparing the rest of the gland. The technique presents a contrast to traditional approaches, where removing the entire prostate leaves patients safe from cancer, but facing profound sexual and urinary side effects.
Focal therapy is a technique of treating only the cancerous areas of the prostate, not affecting the rest of the prostate. The focal therapy program at Mount Sinai will be the first to use fusion biopsy technology to deliver treatment more precisely. Fusion-guided biopsy, an imaging technique which combines MRI and ultrasound imaging to better visualize the prostate during procedures, has been in use at Mount Sinai since 2013 for use in obtaining biopsy samples.
The newly expanded program will be led by Art R. Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology and Associate Professor of Urology and Radiology at the Icahn School of Medicine at Mount Sinai. Dr. Rastinehad, who joined Mount Sinai from the North Shore-LIJ Health System in January, is a recognized leader in the design of the imaging and the screening techniques at the foundation of focal therapy. In collaboration with the National Cancer Institute and Philips Health care, for instance, Dr. Rastinehad helped to develop the first fusion biopsy device.
“We are extremely pleased to welcome Dr. Rastinehad to Mount Sinai,” said Ash Tewari, MD, the Kyung Hyun Kim, MD Chair of Urology at the Mount Sinai Health System and Professor of Urology at the Icahn School of Medicine at Mount Sinai. “I look forward to working with Art to further develop our focal therapy initiative.”
Dr. Rastinehad is the first dual fellowship trained urological oncologist to practice interventional urology. In his new position, he will work with other industry leaders at the Icahn School of Medicine at Mount Sinai to advance a multidisciplinary approach to treating prostate cancer.
Since joining the Mount Sinai Health System, Dr. Rastinehad led the first international course on MRI/US fusion guided biopsies, sponsored by the American Urological Association and hosted at the Icahn School of Medicine at Mount Sinai in December of last year. Dr. Rastinehad will lead future courses at Mount Sinai including one held in March. For more information, visit https://www.auanet.org/education/courses/MRFUS151.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community‐based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care physicians, 12‐minority‐owned free‐standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.
# # #